Gene mutations are significant in the aetiology and progression of illnesses and disorders such as immune system disorders, metabolic diseases, cancer, and in-born genetic disorders. As a result, researchers may use extensive knowledge of the human genome to better understand the aetiology of certain disorders and devise treatment regimens. The growing number of genome projects throughout the world, along with lower genetic analysis costs, aids in the advancement of research in areas such as illness treatment, personalised medicine, and microbial genetics. These procedures necessitate the employment of numerous molecular biology enzymes and reagents, and as a result, the molecular biology enzymes and kits & reagents market is predicted to grow.
Genomic research has grown as a scientific study subject during the last two decades. The genomics sector has seen major technical advances as a result of grants and financing from government entities. R&D investments have given chances for expansion in the molecular biology enzymes and kits & reagents markets. China is one of the world’s top R&D investors, with the country likely to surpass the United States in R&D spending by 2023 (Source: Council on Foreign Relations or CFR). As a result, several corporations have expanded their operations and R&D efforts in China. In 2020, the country’s R&D investment is expected to increase from 10.3% to USD 378 billion (2.44 trillion Chinese yuan).
However, reimbursement regulations for genetic testing are rigid. Unless authorised by a physician, most health insurance plans in the United States do not cover the cost of genetic testing. Coverage and reimbursement are completely determined by the provider’s policy. For example, Medicare covers genetic testing for persons with cancer who qualify for Medicare coverage of genetic testing for an inherited mutation. Such worries are stifling market expansion throughout the world.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Molecular Biology Enzymes and Kits & Reagents Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Molecular Biology Enzymes and Kits & Reagents Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
The segmentation coverage of the study is provided below.
Molecular Biology Enzymes and Kits & Reagents Market based on Product:
- Kits and Reagents
- Enzymes
- Polymerases
- Ligases
- Restriction Endonucleases
- Reverse Transcriptases
- Others
Molecular Biology Enzymes and Kits & Reagents Market based on Application:
- Polymerase Chain Reaction
- Sequencing
- Cloning
- Epigenetics
- Restriction Digestion
- Synthetic Biology
- Others
Molecular Biology Enzymes and Kits & Reagents Market based on End User:
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Hospitals and Diagnostic Centers
- Others
Molecular Biology Enzymes and Kits & Reagents Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
In 2022, kits and reagents had a market share of more than 67.50%. This may be ascribed to the widespread availability of these medications in the market, as well as unique advancements and continuous product releases from important manufacturers, which has been spurred further by the increasing number of SARS-CoV-2 variations. PerkinElmer, for example, announced the December 2021 release of the NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 for disease surveillance and increase of sequencing throughput and reliability for variant detection. The business then released this kit, which is compatible with the Illumina platform, increasing its utilisation rate even more.
Enzymes are expected to increase the quickest throughout the projected period, as cloning technology becomes more common in laboratories and the breadth of molecular biology expands. This has enabled manufacturers and suppliers to provide a variety of enzymes for nucleic acid modification. The availability of many enzyme sources for cloning applications, such as ligases, polymerases, nucleases, methylases, phosphatases, and topoisomerases, has led in the progress of cloning procedures. Furthermore, firms are working to produce unique and enhanced enzymes. For example, Novozymes and Novo Nordisk cooperated in November 2021 to develop specialist enzymes for usage in biopharmaceutical production processes, and new products are likely to be launched over the following few years.
In 2022, the sequencing category led the market, with a revenue share of more than 35.82%. This expansion can be ascribed to the rising use of sequencing-based medicinal therapies and the use of sequencing in cancer. The usage of next-generation sequencing (NGS) for genomes analysis, tumour diagnostics, and biomarker development supports segment expansion and promotes the use of molecular biology consumables in this sector. To drive the segment, major corporations are pursuing various business methods. For example, in January 2022, Pacific Biosciences partnered with Berry Genomics to provide their long-read sequencing technology to the Chinese clinical market. These measures are expected to propel the industry in the near future.
In 2022, the pharma and biotech category held the highest proportion of about 37.44%. This is due to the widespread use of molecular biology products that facilitate workflow, such as PCR, sequencing, genotyping, and DNA/RNA extraction enzymes. The convenience and efficiency of these solutions throughout pharma and biotech businesses’ research for drug candidates, personalised medicine, or diagnostics boosts improvements of offerings and, as a result, sales. Such widespread adoption of molecular technologies by businesses during R&D and clinical trials will boost the market in the approaching years.
In 2022, North America had the highest revenue share of 45.78%. The prevalence of chronic illnesses and the incidence of cancer in the population are driving research activity for preventive and treatment options. As a result, the need for molecular goods rises. The presence of well-established firms, recognised research institutes, aggregated government and private financing, matured healthcare settings, and ease of adoption of new technology are seen as the primary drivers driving income growth in this region.
- This report illustrates the most vital attributes of the Molecular Biology Enzymes and Kits & Reagents Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Molecular Biology Enzymes and Kits & Reagents Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Molecular Biology Enzymes and Kits & Reagents Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Molecular Biology Enzymes and Kits & Reagents Market.
List of Tables
TABLE 1. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR KITS AND REAGENTS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR ENZYMES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR POLYMERASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR LIGASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR RESTRICTION ENDONUCLEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR REVERSE TRANSCRIPTASES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 10. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR POLYMERASE CHAIN REACTION, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR SEQUENCING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR CLONING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR EPIGENETICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR RESTRICTION DIGESTION, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR SYNTHETIC BIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 17. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 18. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 19. MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 20. NORTH AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 21. NORTH AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 22. NORTH AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 23. NORTH AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 24. U.S MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 25. U.S MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. U.S MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 27. CANADA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 28. CANADA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 29. CANADA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 30. MEXICO MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. MEXICO MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 32. MEXICO MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 33. EUROPE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 34. EUROPE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 35. EUROPE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 36. EUROPE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 37. GERMANY MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 38. GERMANY MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. GERMANY MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 40. U.K MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 41. U.K MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 42. U.K MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 43. FRANCE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 44. FRANCE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. FRANCE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 46. ITALY MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 47. ITALY MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. ITALY MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 49. SPAIN MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 50. SPAIN MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. SPAIN MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 52. ROE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 53. ROE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 54. ROE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 55. ASIA PACIFIC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 56. ASIA PACIFIC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 57. ASIA PACIFIC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. ASIA PACIFIC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 59. CHINA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 60. CHINA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 61. CHINA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 62. INDIA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 63. INDIA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 64. INDIA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 65. JAPAN MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 66. JAPAN MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 67. JAPAN MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 68. REST OF APAC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 69. REST OF APAC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 70. REST OF APAC MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 71. LATIN AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 72. LATIN AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 73. LATIN AMERICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 74. BRAZIL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 75. BRAZIL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 76. BRAZIL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 77. ARGENTINA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 78. ARGENTINA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 79. ARGENTINA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 80. MIDDLE EAST AND AFRICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 81. MIDDLE EAST AND AFRICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 82. MIDDLE EAST AND AFRICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 83. SAUDI ARABIA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 84. SAUDI ARABIA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 85. SAUDI ARABIA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 86. UAE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 87. UAE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 88. UAE MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 89. REST OF MIDDLE EAST AND AFRICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 90. REST OF MIDDLE EAST AND AFRICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 91. REST OF MIDDLE EAST AND AFRICA MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 92. LGC LIMITED : FINANCIALS
TABLE 93. LGC LIMITED : PRODUCTS & SERVICES
TABLE 94. LGC LIMITED : RECENT DEVELOPMENTS
TABLE 95. PROMEGA CORPORATION: FINANCIALS
TABLE 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
TABLE 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
TABLE 98. MERCK KGAA: FINANCIALS
TABLE 99. MERCK KGAA: PRODUCTS & SERVICES
TABLE 100. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 101. NEW ENGLAND BIOLABS: FINANCIALS
TABLE 102. NEW ENGLAND BIOLABS: PRODUCTS & SERVICES
TABLE 103. NEW ENGLAND BIOLABS: RECENT DEVELOPMENTS
TABLE 104. ILLUMINA INC.: FINANCIALS
TABLE 105. ILLUMINA INC.: PRODUCTS & SERVICES
TABLE 106. ILLUMINA INC.: RECENT DEVELOPMENTS
TABLE 107. TAKARA BIO INC.: FINANCIALS
TABLE 108. TAKARA BIO INC.: PRODUCTS & SERVICES
TABLE 109. TAKARA BIO INC.: RECENT DEVELOPMENTS
TABLE 110. BIO-RAD LABORATORIES INC.: FINANCIALS
TABLE 111. BIO-RAD LABORATORIES INC.: PRODUCTS & SERVICES
TABLE 112. BIO-RAD LABORATORIES INC.: DEVELOPMENTS
TABLE 113. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS
TABLE 114. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES
TABLE 115. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS
TABLE 116. F.HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 117. F.HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 118. F.HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 119. QIAGEN: FINANCIALS
TABLE 120. QIAGEN: PRODUCTS & SERVICES
TABLE 121. QIAGEN: RECENT DEVELOPMENTS
